ArticleJournal of hematology & oncology2017

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.

P Balsas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.